CytOSorb TreatMent Of Critically Ill PatientS Registry

ConditionsSeptic Shock Acute Respiratory Distress Syndrome Trauma Rhabdomyolysis Cardiogenic Shock Pancreatitis Acute on Chronic Liver Failure Acute Liver Failure Burns Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)Extracorporeal Life Support Postoperative Endocarditis Hemophagocytic Lymphohistiocytoses Liver Transplant; Complications Infectious Disease Postoperative Vasoplegic Syndrome Drug Overdose Sepsis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorCytoSorbents, Inc

About this trial

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Eligibility criteria

Qualifiers

Planned OR actual CytoSorb® 300 mL device utilization

Informed consent for prospective registry participation

Disqualifiers

Use of the CytoSorb® 300 mL device for antithrombotic removal only

Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only

The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Trial design

Treatments tested in this trial

CytoSorb

Treatment groups

No treatment groups listed

Locations

Austria

Klinikum Klagenfurt am Wörthersee9020, Klagenfurt Austria

Medizinische Universität Wien1090, Vienna Austria

Germany

Universitätsklinikum Aachen52074, Aachen Germany

Herz- und Diabeteszentrum Nordrhein-Westfalen32545, Bad Oeynhausen Germany

Sponsors and collaborators

CytoSorbents, Inc

Lead sponsor

Source ClinicalTrials.gov